Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System (NCT07406490)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this observational study is to develop, implement, and evaluate a machine learning algorithm-based Hepatitis C Emergency Department (HepC-EnD) screening tool for use in emergency departments (EDs) to identify patients at high risk of hepatitis C virus (HCV) infection. HepC-EnD will be integrated into the University of Florida Health electronic health record (EHR) system as a best practice alert (BPA) pop-up for ED providers, notifying them of patients at high risk for HCV infection and recommending both HCV and human immunodeficiency virus (HIV) screening. Investigators aim to enhance the screening and diagnosis of individuals who may otherwise remain undiagnosed and untreated. The implementation outcomes (e.g., usability) and effectiveness outcomes (e.g., HCV screening and diagnosis rates) of HepC-EnD targeted screening will be compared with universal screening (FOCUS) and conventional physician-initiated screening programs in EDs.
Who can join: Review the eligibility criteria below.
Location: UF Health Shands Emergency Room / Trauma Center — Gainesville, Florida
Age range: 18 Years to 79 Years
🧪 Interventions in This Study
- Physician-Initiated Screening (Conventional Screening) (OTHER)
- FOCUS (Universal Screening) (OTHER)
- HepC-EnD (Targeted Screening) (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- UF Health Shands Emergency Room / Trauma Center — Gainesville, Florida
- UF Health Jacksonville Emergency Room — Jacksonville, Florida
- UF Health North Emergency Room — Jacksonville, Florida
📞 Contact the Study Coordinator
Phone: (352) 273-6261
Email: hpark@cop.ufl.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatitis C Virus (HCV)
- Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data — Vancouver, British Columbia
Explore by condition: All Hepatitis C Virus (HCV) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.